Abstract
Purpose
To compare the efficacy and safety of combination therapy with orbital irradiation and systemic steroids versus steroid monotherapy in the management of active Graves’ orbitopathy (GO).
Methods
The clinical charts of 127 patients with active inflammation due to GO who received intravenous steroid pulse therapy as a first-line treatment with or without orbital radiotherapy between 2010 and 2014 were reviewed. Patients were divided into two treatment groups: 1) combined orbital radiotherapy and steroid pulse therapy (SRT group) and 2) steroid pulse therapy only (ST group). Primary outcome measures included clinical activity score (CAS); NOSPECS classification; ocular motility impairment; and exophthalmos at 1, 3, 6, and 12 months after treatment. The secondary outcome measure was the change in orbital, extraocular muscle (EOM), and fat volume after treatment measured by orbit computed tomography.
Results
Sixty-eight patients were included in the SRT group, and 59 patients were in the ST group. In both treatments, CAS and NOSPECS were significantly reduced. In the comparison of the degree of change from baseline between the groups, the SRT group demonstrated more improvement in NOSPECS and scores of ocular motility. Orbital, EOM, and fat volume significantly decreased in the SRT group; however, only fat volume was reduced in the ST group. Compressive optic neuropathy after treatment developed in 0 % of the SRT group and 3.4 % (2/59) of the ST group. Reactivation of inflammation occurred in 11.8 % (8/68) of the SRT group and 28.8 % (17/59) of the ST group.
Conclusions
Orbital radiotherapy in combination with steroid treatment significantly improved ocular motility by reducing EOM volume in patients with active GO.
Similar content being viewed by others
References
Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P, Marcocci C, Mourits M, Perros P, Boboridis K, Boschi A, Curro N, Daumerie C, Kahaly GJ, Krassas GE, Lane CM, Lazarus JH, Marino M, Nardi M, Neoh C, Orgiazzi J, Pearce S, Pinchera A, Pitz S, Salvi M, Sivelli P, Stahl M, von Arx G, Wiersinga WM (2008) Consensus statement of the European Group on Graves’ orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 158(3):273–285. doi:10.1530/eje-07-0666
Bartalena L, Fatourechi V (2014) Extrathyroidal manifestations of Graves’ disease: a 2014 update. J Endocrinol Invest 37(8):691–700. doi:10.1007/s40618-014-0097-2
Marcocci C, Bartalena L, Tanda ML, Manetti L, Dell’Unto E, Rocchi R, Barbesino G, Mazzi B, Bartolomei MP, Lepri P, Cartei F, Nardi M, Pinchera A (2001) Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves’ ophthalmopathy: results of a prospective, single-blind, randomized study. J Clin Endocrinol Metab 86(8):3562–3567. doi:10.1210/jcem.86.8.7737
Kahaly GJ, Pitz S, Hommel G, Dittmar M (2005) Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves’ orbitopathy. J Clin Endocrinol Metab 90(9):5234–5240. doi:10.1210/jc.2005-0148
Zang S, Ponto KA, Kahaly GJ (2011) Clinical review: intravenous glucocorticoids for Graves’ orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab 96(2):320–332. doi:10.1210/jc.2010-1962
Macchia PE, Bagattini M, Lupoli G, Vitale M, Vitale G, Fenzi G (2001) High-dose intravenous corticosteroid therapy for Graves’ ophthalmopathy. J Endocrinol Invest 24(3):152–158
Prummel MF, Mourits MP, Berghout A, Krenning EP, van der Gaag R, Koornneef L, Wiersinga WM (1989) Prednisone and cyclosporine in the treatment of severe Graves’ ophthalmopathy. N Engl J Med 321(20):1353–1359. doi:10.1056/nejm198911163212002
Nagayama Y, Izumi M, Kiriyama T, Yokoyama N, Morita S, Kakezono F, Ohtakara S, Morimoto I, Okamoto S, Nagataki S (1987) Treatment of Graves’ ophthalmopathy with high-dose intravenous methylprednisolone pulse therapy. Acta Endocrinol (Copenh) 116(4):513–518
Guy JR, Fagien S, Donovan JP, Rubin ML (1989) Methylprednisolone pulse therapy in severe dysthyroid optic neuropathy. Ophthalmology 96(7):1048–1052, discussion 1052–1043
Hiromatsu Y, Tanaka K, Sato M, Kuroki T, Nonaka K, Kojima K, Nishimura H, Nishida H, Kaise N (1993) Intravenous methylprednisolone pulse therapy for Graves’ ophthalmopathy. Endocr J 40(1):63–72
Tanda ML, Bartalena L (2012) Efficacy and safety of orbital radiotherapy for graves’ orbitopathy. J Clin Endocrinol Metab 97(11):3857–3865. doi:10.1210/jc.2012-2758
Kazim M, Garrity JA (2012) Orbital radiation therapy for thyroid eye disease. J Neuroophthalmol 32(2):172–176. doi:10.1097/WNO.0b013e318255d7c7
Gorman CA, Garrity JA, Fatourechi V, Bahn RS, Petersen IA, Stafford SL, Earle JD, Forbes GS, Kline RW, Bergstralh EJ, Offord KP, Rademacher DM, Stanley NM, Bartley GB (2001) A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves’ ophthalmopathy. Ophthalmology 108(9):1523–1534
Ruchala M, Hernik A, Zybek A (2014) Orbital radiotherapy in the management of Graves’ orbitopathy--current state of knowledge. Endokrynol Pol 65(5):388–396. doi:10.5603/ep.2014.0054
Mourits MP, Prummel MF, Wiersinga WM, Koornneef L (1997) Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy. Clin Endocrinol (Oxf) 47(1):9–14
Eckstein AK, Plicht M, Lax H, Neuhauser M, Mann K, Lederbogen S, Heckmann C, Esser J, Morgenthaler NG (2006) Thyrotropin receptor autoantibodies are independent risk factors for Graves’ ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 91(9):3464–3470. doi:10.1210/jc.2005-2813
Regensburg NI, Kok PH, Zonneveld FW, Baldeschi L, Saeed P, Wiersinga WM, Mourits MP (2008) A new and validated CT-based method for the calculation of orbital soft tissue volumes. Invest Ophthalmol Vis Sci 49(5):1758–1762. doi:10.1167/iovs.07-1030
Mourits MP, van Kempen-Harteveld ML, Garcia MB, Koppeschaar HP, Tick L, Terwee CB (2000) Radiotherapy for Graves’ orbitopathy: randomised placebo-controlled study. Lancet 355(9214):1505–1509. doi:10.1016/s0140-6736(00)02165-6
Prummel MF, Mourits MP, Blank L, Berghout A, Koornneef L, Wiersinga WM (1993) Randomized double-blind trial of prednisone versus radiotherapy in Graves’ ophthalmopathy. Lancet 342(8877):949–954
Bradley EA, Gower EW, Bradley DJ, Meyer DR, Cahill KV, Custer PL, Holck DE, Woog JJ (2008) Orbital radiation for graves ophthalmopathy: a report by the American Academy of Ophthalmology. Ophthalmology 115(2):398–409. doi:10.1016/j.ophtha.2007.10.028
Ng CM, Yuen HK, Choi KL, Chan MK, Yuen KT, Ng YW, Tiu SC (2005) Combined orbital irradiation and systemic steroids compared with systemic steroids alone in the management of moderate-to-severe Graves’ ophthalmopathy: a preliminary study. Hong Kong Med J 11(5):322–330
Curtis JR, Westfall AO, Allison J, Bijlsma JW, Freeman A, George V, Kovac SH, Spettell CM, Saag KG (2006) Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum 55(3):420–426. doi:10.1002/art.21984
Gorman CA, Garrity JA, Fatourechi V, Bahn RS, Petersen IA, Stafford SL, Earle JD, Forbes GS, Kline RW, Buettner H, Robertson DM, Bergstralh EJ, Offord KP, Rademacher DM, Stanley NM, Bartley GB (2002) The aftermath of orbital radiotherapy for graves’ ophthalmopathy. Ophthalmology 109(11):2100–2107
Wu Y, Tong B, Luo Y, Xie G, Xiong W (2015) Effect of radiotherapy on moderate and severe thyroid associated ophthalmopathy: a double blind and self-controlled study. Int J Clin Exp Med 8(2):2086–2096
Shams PN, Ma R, Pickles T, Rootman J, Dolman PJ (2014) Reduced risk of compressive optic neuropathy using orbital radiotherapy in patients with active thyroid eye disease. Am J Ophthalmol 157(6):1299–1305. doi:10.1016/j.ajo.2014.02.044
Hahn E, Laperriere N, Millar BA, Oestreicher J, McGowan H, Krema H, Gill H, DeAngelis D, Hurwitz J, Tucker N, Simpson R, Chung C (2014) Orbital radiation therapy for Graves’ ophthalmopathy: measuring clinical efficacy and impact. Pract Radiat Oncol 4(4):233–239. doi:10.1016/j.prro.2014.02.008
Wakelkamp IM, Tan H, Saeed P, Schlingemann RO, Verbraak FD, Blank LE, Prummel MF, Wiersinga WM (2004) Orbital irradiation for Graves’ ophthalmopathy: Is it safe? A long-term follow-up study. Ophthalmology 111(8):1557–1562. doi:10.1016/j.ophtha.2003.12.054
Bartalena L, Marcocci C, Manetti L, Tanda ML, Dell’Unto E, Rocchi R, Cartei F, Pinchera A (1998) Orbital radiotherapy for Graves’ ophthalmopathy. Thyroid 8(5):439–441
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
For this type of study, formal consent is not required.
Funding
This work was supported by the Bio & Medical Technology Development Program of the National Research Foundation(NRF) funded by the Korean government (grant number NRF-2015M3A9E2067031). The sponsor had no role in the design or conduct of this research.
Conflict of interest
All authors certify that they have NO affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Supplementary Fig. 1
Flow diagram of inclusion for study subjects (JPG 369 kb)
Supplementary Table 1
(DOCX 28 kb)
Rights and permissions
About this article
Cite this article
Kim, J.W., Han, S.H., Son, B.J. et al. Efficacy of combined orbital radiation and systemic steroids in the management of Graves’ orbitopathy. Graefes Arch Clin Exp Ophthalmol 254, 991–998 (2016). https://doi.org/10.1007/s00417-016-3280-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00417-016-3280-7